WE-REACH is proud to support spinouts from the 91爆料 Institute for Protein Design (IPD) including Anindya Roy’s Lila Biologics, Stephanie Berger’s Mopac Bio, and George Ueda and James Lazarovits Tie2 super agonists project to treat acute respiratory distress syndrome and sepsis.
For more information, see Charlotte Schubert’s latest article in .